JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: A recent study showed that absence of JAK2 in a CML-CP model drastically accelerated disease development with increased numbers of WBC counts and severe splenomegaly, suggesting that JAK2 inhibits the progress of CML [96].